|
Two new members appointed to LIDDS´ Board |
|
|
Friday, 18 June 2010 |
|
At LIDDS´Annual Meeting in May two new members were appointed to the Board, Michael Oredsson and Jonas Rastad (see more under Company ). Michael Oredsson was also appointed Chairman of the Board.
|
|
LIDDS’ share offering was fully subscribed |
|
|
Friday, 19 February 2010 |
The total number of shares issued was 963 842 at a share price of SEK 12 per share.
|
|
Read more >
|
|
Extended application period for the share offering |
|
|
Wednesday, 10 February 2010 |
LIDDS´ board have decided to extend the application period for the share offering until 17.00, Friday, February 12.
|
|
New share offering. |
|
|
Friday, 29 January 2010 |
|
LIDDS will raise up to SEK 11.6m through a new share offering of a maximum of 963,842 new shares.
|
|
Read more >
|
|
Approval to start phase II study |
|
|
Thursday, 02 July 2009 |
LIDDS has received approval from the National
Agency of Medicine and Ethical Committee in Finland to start a phase II study in patients with
localized prostate cancer.
|
|
Read more >
|
|
LIDDS presentation film |
|
|
Thursday, 06 December 2007 |
|
We have now made the LIDDS presentation film available here at our website. It features a presentation of Liproca® and the LIDDS project. You will find it under the section The Company/Company Presentations.
|
|
More LIDDS on CNBC Europe |
|
|
Thursday, 08 November 2007 |
|
There will be more of LIDDS on CNBC Europe, November 13 and 14 at 12.30, 12.47 and 12.57 CET. Like the previous broadcast the presentation of LIDDS will feature three consecutive two-minute sequences. Please note that the actual broadcasting moment may vary, up to +/- 20 minutes.
|
|
LIDDS on CNBC Europe |
|
|
Wednesday, 17 October 2007 |
|
A LIDDS film will be broadcasted on CNBC Europe on Friday October 19. The spot will be sent in three two-minute parts at 11.07 AM, 11.30 AM and 11.47 AM (CET). The whole six-minute film will later be
accessible on LIDDS website.
|
|
First Patient Treated With Liproca® |
|
|
Tuesday, 10 July 2007 |
|
LIDDS first
product Liproca® Implant, an antiandrogen
containing, injectable, controlled release product intended for local treatment
of prostate cancer is under clinical testing in patients diagnosed with
prostate cancer and scheduled for prostatectomy at Sahlgrenska Hospital,
Gothenburg, Sweden.
|
|
Read more >
|
|
LIDDS AB completes SEK 40 million financing. |
|
|
Monday, 19 March 2007 |
|
LIDDS AB completes SEK 40 million financing (MEUR 4,4) for development of prostate cancer treatment and other disease therapies.
|
|
Read more >
|
|
